$NBIO News February 23, 2022 The Agreement grants
Post# of 47038
(Total Views: 165)
Posted On: 02/23/2022 10:48:16 AM
$NBIO News February 23, 2022
The Agreement grants to BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America. Under terms of the Agreement, Nascent will receive a total of USD $5,000,000 to be paid out at various stipulated milestones. The initial payment of USD $1,000,000 was received by Nascent on April 20, 2021.
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical https://finance.yahoo.com/news/nascent-biotec...00418.html
The Agreement grants to BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America. Under terms of the Agreement, Nascent will receive a total of USD $5,000,000 to be paid out at various stipulated milestones. The initial payment of USD $1,000,000 was received by Nascent on April 20, 2021.
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical https://finance.yahoo.com/news/nascent-biotec...00418.html
(0)
(0)Scroll down for more posts ▼